Insmed Inc INSM

Healthcare Biotechnology

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disea...

NDAQ:INSM - Post by User

Insmed Inc

<< Previous

Bullboard Posts

Next >>

(0)
•••

Post by jamieb3on Dec 26, 2006 4:33pm

316 Views

Post# 11921439

down to 80 cents this AM

I keep looking at this stock. It was down as low as 80 cents and closed at 87. They lost the infringment case to TRCA and DNA, but have European approval. Hard to say what is going to happen. They made a better drug.

<< Previous

Bullboard Posts

Next >>

The 5-Minute Investor Podcast, Ep. 61: Water stocks making waves